FDA Grants Priority Review to Merck ’s Supplemental Biologics License Application (sBLA) Seeking Approval for KEYTRUDA® (pembrolizumab) for New Indication in Microsatellite Instability-High Cancer
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA)
accepted for review the supplemental Biologics License Application
(sBLA) for KEYTRUDA® (pembrolizumab), the company ’s anti-PD-1
therapy, for the treatment of previously treated patients with advanced
microsatellite instability-high (MSI-H) cancer.Language:
EnglishContact: MerckMedia:Pamela Eisele, 267-305-3558orKim Hamilton, 908-740-1863orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898Ticker Slug:Ticker:MRKExchange:NYSEread more
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK Keytruda MSD Source Type: news
More News: Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | Grants | Merck | Pharmaceuticals